Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

TRACERx, a prospective study of patients with primary non-small cell lung cancer, aims to map the genomic landscape of lung cancer by tracking clonal heterogeneity and tumour evolution from diagnosis to relapse.

Mark Cobbold | Iftekhar Khan | Caroline Dive | Ged Brady | Gary Middleton | Bruno Morgan | Charles Swanton | Martin Forster | Mariam Jamal-Hanjani | Nicholas McGranahan | Nicolai Juul Birkbak | Selvaraju Veeriah | Sean Smith | Leena Joseph | Marianne Nicolson | Mairead MacKenzie | Keith Kerr | Mary Falzon | R. Booton | H. Davies | S. Horswell | M. Salm | C. Swanton | K. Kerr | M. Jamal-Hanjani | S. Veeriah | A. Hackshaw | S. Quezada | B. Morgan | N. Birkbak | D. Fennell | M. Nicolson | K. Peggs | M. Cobbold | M. Wilcox | C. Pritchard | C. Dive | F. Blackhall | D. Lawrence | M. Falzon | D. Waller | I. Woolhouse | D. Nonaka | N. Murugaesu | J. Lester | S. Janes | M. Chetty | Nik Matthews | S. Lee | M. Forster | T. Ahmad | Y. Summers | R. Shah | P. Crosbie | B. Naidu | G. Middleton | G. Langman | H. Remmen | M. Kornaszewska | R. Attanoos | Haydn Adams | N. Iles | Y. Ngai | R. Mitter | M. Krebs | E. D. de Bruin | J. Goldman | E. Smith | G. Brady | J. Bennett | K. Buchan | M. Mackenzie | Sean Smith | Fiona Blackhall | Elza de Bruin | Karl Peggs | I. Khan | Daisuke Nonaka | Sam Janes | Helen Davies | Richard Booton | John Le Quesne | Seema Shafi | Andrew Rowan | Nik Matthews | Tanya Ahmad | David Lawrence | Yvonne Summers | Rajesh Shah | Babu Naidu | Gerald Langman | Hardy Remmen | Mahendran Chetty | Dean Fennell | Jason Lester | Malgorzata Kornaszewska | Richard Attanoos | Haydn Adams | Natasha Iles | Yenting Ngai | Stuart Horswell | Max Salm | Richard Mitter | Nirupa Murugaesu | J. Shaw | David Waller | Catrin Pritchard | Jacqueline Shaw | Maggie Wilcox | Tom Haswell | Matthew Krebs | Alan Hackshaw | Sergio Quezada | Siow-Ming Lee | Salli Muller | Aengus Stuart | Jonathan Bennett | Keith Buchan | Arrigo Capitano | Philip Crosbie | Alan Denison | Madhav Djearman | Jacki Goldman | Joy Millar | Elaine Smith | Magali Taylor | Ben Wilcox | Ian Woolhouse | A. Denison | Magali N. Taylor | N. Mcgranahan | S. Shafi | A. Rowan | T. Haswell | L. Joseph | J. Le Quesne | S. Muller | A. Stuart | A. Capitano | Madhav Djearman | J. Millar | B. Wilcox | R. Shah

[1]  J. Uhm.  Clonal selection drives genetic divergence of metastatic medulloblastoma , 2012 .

[2]  I. Tomlinson,et al.  Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. , 2010, Gastroenterology.

[3]  Kenric Leung,et al.  The Life History of 21 Breast Cancers , 2015, Cell.

[4]  Niruthika Sritharan,et al.  Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.

[5]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[7]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[8]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[9]  T. Mok,et al.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. , 2012, The oncologist.

[10]  Karen Page,et al.  Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. , 2012, Genome research.

[11]  Charles Swanton,et al.  Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.

[12]  Jungsil Ro,et al.  Micropapillary Component in Lung Adenocarcinoma: A Distinctive Histologic Feature With Possible Prognostic Significance , 2002, The American journal of surgical pathology.

[13]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[14]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[15]  Replication stress links structural and numerical cancer chromosomal instability (vol 494, pg 492, 2013) , 2013 .

[16]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[17]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[18]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[19]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[20]  Jing Pan,et al.  Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. , 2012, Carcinogenesis.

[21]  B. Carter.  A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma , 2013 .

[22]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[23]  Xiaohong Li,et al.  A Comprehensive Survey of Clonal Diversity Measures in Barrett's Esophagus as Biomarkers of Progression to Esophageal Adenocarcinoma , 2010, Cancer Prevention Research.

[24]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Debyani Chakravarty,et al.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.

[26]  L. Chirieac,et al.  Prognostic significance of grading in lung adenocarcinoma , 2010, Cancer.

[27]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[28]  C. Swanton.  Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.

[29]  Y. Ishikawa,et al.  Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. , 2009, Lung cancer.

[30]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[31]  J. Troge,et al.  Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.

[32]  Karsten Schlüns,et al.  Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. , 2009, Lung cancer.

[33]  Charles Swanton,et al.  Breast cancer genome heterogeneity: a challenge to personalised medicine? , 2011, Breast Cancer Research.

[34]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[35]  Nicolai J. Birkbak,et al.  Chromosomal instability confers intrinsic multidrug resistance. , 2011, Cancer research.

[36]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[37]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[38]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[39]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[40]  田中 寿明.  Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1 , 2008 .

[41]  C. Swanton,et al.  Cancer chromosomal instability: therapeutic and diagnostic challenges , 2012, EMBO reports.

[42]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[43]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[44]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[45]  Peter J. Campbell,et al.  Evolution of the cancer genome , 2012, Nature Reviews Genetics.

[46]  Huanming Yang,et al.  Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor , 2012, Cell.

[47]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[48]  M. Tsuboi,et al.  Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.

[49]  J. Allison,et al.  Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. , 2007, Cancer cell.

[50]  Sung-Liang Yu,et al.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[52]  K. Kinzler,et al.  Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.

[53]  三好 立,et al.  Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis , 2003 .

[54]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[55]  Thomas J. Hardcastle,et al.  Chromosomal instability determines taxane response , 2009, Proceedings of the National Academy of Sciences.

[56]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.